These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9605396)

  • 1. Combined immunoglobulin and azathioprine in multiple sclerosis.
    Kalanie H; Tabatabai SS
    Eur Neurol; 1998; 39(3):178-81. PubMed ID: 9605396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis.
    Achiron A; Pras E; Gilad R; Ziv I; Mandel M; Gordon CR; Noy S; Sarova-Pinhas I; Melamed E
    Arch Neurol; 1992 Dec; 49(12):1233-6. PubMed ID: 1449400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.
    Lus G; Romano F; Scuotto A; Accardo C; Cotrufo R
    Eur Neurol; 2004; 51(1):15-20. PubMed ID: 14631124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in multiple sclerosis, Part 2.
    Becker CC; Gidal BE; Fleming JO
    Am J Health Syst Pharm; 1995 Oct; 52(19):2105-20; quiz 2132-4. PubMed ID: 8535945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study.
    Fazekas F; Deisenhammer F; Strasser-Fuchs S; Nahler G; Mamoli B
    Mult Scler; 1997 Apr; 3(2):137-41. PubMed ID: 9291168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of azathioprine in relapsing-remitting multiple sclerosis.
    Goodkin DE; Bailly RC; Teetzen ML; Hertsgaard D; Beatty WW
    Neurology; 1991 Jan; 41(1):20-5. PubMed ID: 1985289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group.
    Fazekas F; Deisenhammer F; Strasser-Fuchs S; Nahler G; Mamoli B
    Lancet; 1997 Mar; 349(9052):589-93. PubMed ID: 9057729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results.
    Sørensen PS; Wanscher B; Schreiber K; Blinkenberg M; Jensen CV; Ravnborg M
    Mult Scler; 1997 Apr; 3(2):145-8. PubMed ID: 9291170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.
    Massacesi L; Tramacere I; Amoroso S; Battaglia MA; Benedetti MD; Filippini G; La Mantia L; Repice A; Solari A; Tedeschi G; Milanese C
    PLoS One; 2014; 9(11):e113371. PubMed ID: 25402490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-specific immunosuppressants in the treatment of multiple sclerosis.
    Confavreux C; Vukusic S
    Clin Neurol Neurosurg; 2004 Jun; 106(3):263-9. PubMed ID: 15177781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis.
    Sorensen PS; Wanscher B; Jensen CV; Schreiber K; Blinkenberg M; Ravnborg M; Kirsmeier H; Larsen VA; Lee ML
    Neurology; 1998 May; 50(5):1273-81. PubMed ID: 9595974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
    Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Morrissey SP; Edan G
    J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):52-6. PubMed ID: 17846110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.
    Achiron A; Gabbay U; Gilad R; Hassin-Baer S; Barak Y; Gornish M; Elizur A; Goldhammer Y; Sarova-Pinhas I
    Neurology; 1998 Feb; 50(2):398-402. PubMed ID: 9484361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azathioprine for multiple sclerosis.
    Casetta I; Iuliano G; Filippini G
    J Neurol Neurosurg Psychiatry; 2009 Feb; 80(2):131-2; discussion 132. PubMed ID: 19151017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intravenous immunoglobulins in therapy of intermittent multiple sclerosis. An update].
    Fazekas F; Strasser-Fuchs S; Hartung HP
    Nervenarzt; 1998 Apr; 69(4):361-5. PubMed ID: 9606690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis--results of the German multicenter study.
    Kappos L; Patzold U; Dommasch D; Poser S; Haas J; Krauseneck P; Malin JP; Fierz W; Graffenried BU; Gugerli US
    Ann Neurol; 1988 Jan; 23(1):56-63. PubMed ID: 3278672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in multiple sclerosis, Part 1.
    Becker CC; Gidal BE; Fleming JO
    Am J Health Syst Pharm; 1995 Sep; 52(18):1985-2000. PubMed ID: 8528866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous immunoglobulin, plasmalymphocytapheresis and azathioprine in chronic progressive multiple sclerosis.
    Uccelli A; Capello E; Fenoglio D; Incagliato M; Valbonesi M; Mancardi GL
    Ital J Neurol Sci; 1994 Feb; 15(1):51-3. PubMed ID: 8206747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
    Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
    J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.